We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our
Cookie Policy
.
Accept
Label
Search
SKIP TO CONTENT
SKIP NAVIGATION
Drug News
Trending
Commercial Operations
GMPs
FDA Enforcement Actions
Inspections and Audits
Postmarket Safety
Quality
Regulatory Affairs
Research and Development
Submissions and Approvals
FDAnews
Device News
Trending
Commercial Operations
FDA Enforcement Actions
Inspections and Audits
Postmarket Safety
Quality
Regulatory Affairs
Research and Development
Submissions and Approvals
FDAnews
Books
FDAnews Books Library
Drug Books
Device Books
Training/Events
Webinar Training Pass
Events
Webinar Recordings
Resources
Form 483s Database
FDA Approved Drugs
CenterWatch
WCG Clinical
Sign In
Create Account
Sign Out
My Account
Home
»
Authors
» Gisselle I. Sensebe
Gisselle I. Sensebe
Products
PRODUCTS
Scientific Supplies & Technology, Inc.
Gisselle I. Sensebe
Price:
$117.00
View
Boca Dental Regenerative, LLC
Gisselle I. Sensebe
Price:
$117.00
View
Gutizmultiservices, Inc.
Ebony D. Sanon
and
Gisselle I. Sensebe
Price:
$117.00
View
Biomedical Regenerative GF, LLC
Gisselle I. Sensebe
Price:
$117.00
View
Agora Edge
Gisselle I. Sensebe
Price:
$117.00
View
FloSpine, LLC
Gisselle I. Sensebe
Price:
$117.00
View
Prime Lab USA, Corp.
Karen M. Rodriguez
and
Gisselle I. Sensebe
Price:
$117.00
View
Legend Aerospace, Inc.
Karen M. Rodriguez
and
Gisselle I. Sensebe
Price:
$117.00
View
Michael D. Williams, D.D.S., P.A.
Dianiris C. Ayala
and
Gisselle I. Sensebe
Price:
$117.00
View
MobileHelp, LLC
Monica C. Burgos Garcia
and
Gisselle I. Sensebe
Price:
$117.00
View
View All Products by Gisselle I. Sensebe
Upcoming Events
21
Oct
MAGI@home Clinical Research Conference 2024
Featured Products
FDA, FTC and DOJ Enforcement of Medical Device Regulations
Using Real-World Evidence in Drug and Device Submissions
Featured Stories
Risk of 10 Obesity-Driven Cancers Reduced by GLP-1s, Study Says
Three Device Areas Added to CDRH’s Device-Advancing TAP Program
Third Alzheimer’s Drug Gets FDA Approval, Just as Diagnostic Criteria Expand
Draft Guidance Covers Using URRAs in Combo Product Applications
The Revised ICH E8:
A Guide to New Clinical Trial Requirements
Learn More